Login to Your Account

Magenta lands $48.5M series A, aims to rewrite stem cell transplant rules

By Marie Powers
News Editor

Wednesday, November 16, 2016

After quietly incubating for a year, Magenta Therapeutics burst onto the cell therapy scene with a $48.5 million A round to advance its goal of transforming stem cell transplantation for patients with autoimmune diseases, genetic blood disorders and cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription